FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
26 mars 2024 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd...
FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
26 févr. 2024 16h06 HE
|
FibroGen, Inc.
• Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate...
FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea
26 févr. 2024 16h05 HE
|
FibroGen, Inc.
The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place FibroGen to explore licensing opportunities for Roxadustat SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- FibroGen,...
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
20 févr. 2024 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close....
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
09 déc. 2023 17h02 HE
|
FibroGen, Inc.
please call Meichiel Keenan@650-219-6482 with any questions.
FibroGen Reports Second Quarter 2023 Financial Results
07 août 2023 16h01 HE
|
FibroGen, Inc.
Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic...
FibroGen Reports Third Quarter 2022 Financial Results
07 nov. 2022 16h01 HE
|
FibroGen, Inc.
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat...
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
07 nov. 2022 16h00 HE
|
FibroGen, Inc.
Strengthens balance sheet with strategic non-dilutive capital to support strategic prioritiesSupported by global launches of EVRENZO™ in the territories partnered with Astellas Pharma Inc.FibroGen...
FibroGen to Participate at Stifel 2022 Healthcare Conference
01 nov. 2022 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022...
FibroGen Announces Completion of Patient Enrollment in MATTERHORN, a Phase 3 Clinical Study of Roxadustat for the Treatment of Anemia in Patients with Lower Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)
26 août 2022 07h00 HE
|
FibroGen, Inc.
- 141 MDS Patients Enrolled -- Topline Data Anticipated 1H:2023 - SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for...